Clinical trials: Hematological Neoplasm
Leukemia, CART Therapy
Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever
Pre-neutropenic fever (PNF) (fever following chemotherapy but before developing low white cells) and neutropenic fever (NF) (fever in the setting of low white cells) are very common after chemotherapy for acute leukemia, bone…
- Conditions
- Leukemia, CART Therapy, Transplantation, Stem Cell, Infections, Bacterial
- Trial name
- ELSA-Adult (NCT07051525)
- Testing
- Early antibiotic cessation alert
- Where
- 2 sites in Australia
- Volunteers
- 214 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
- Trial name
- NCT00825487
- Testing
- ARQ 621
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Anemia, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
This clinical trial studies how well donor stem cell boost works in treating patients with low blood cells after donor stem cell transplant.
- Conditions
- Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia, Neutropenia
- Trial name
- NCT01660347
- Testing
- Allogeneic hematopoietic stem cell transplantation, Peripheral blood stem cell transplantation, Management of therapy complications
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and…
- Trial name
- NCT03425526
- Testing
- Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Neoplasms
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and…
- Trial name
- NCT07629726
- Testing
- KK2430
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Lung Neoplasm Malignant
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of…
- Trial name
- BUDDY (NCT04059887)
- Testing
- Atezolizumab Injection [Tecentriq]
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chonnam National University Hospital
GVHD, Chronic, Hematological Malignancy
Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT
A two sited feasibility study to test the feasibility of systematic symptom identification with disease specific and clinically developed PROM (Lee Symptom Scale) longitudinally with a 12 month follow up in outpatient care in…
- Trial name
- SIMPly-CARE (NCT04884204)
- Testing
- Lee Symptom Scala
- Where
- Denmark
- Volunteers
- 35 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Solid Tumor, Hematological Malignancy
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease.
- Trial name
- BIP (NCT02534649)
- Testing
- Newly obtained biopsy and Blood samples collection
- Where
- 7 sites in France
- Volunteers
- 10,000 people
- Sponsor
- Institut Bergonié
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies
A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
- Trial name
- NCT04689204
- Testing
- CTA30X
- Where
- China
- Volunteers
- 3 people
- Sponsor
- He Huang
Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called maplirpacept (PF-07901801)) when taken for the treatment of lymphoma or multiple myeloma (a type of cancer that affects…
- Trial name
- NCT05567887
- Testing
- maplirpacept (PF-07901801)
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Pfizer
AML, MDS
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide…
- Conditions
- AML, MDS, Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07493538
- Testing
- Treosulfan, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory Hematological Malignancies
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
This is a single arm, open-label, single center study to determine the safety and efficacy of CNCT19 in adult patients with Relapsed or Refractory B cell Malignancies.
- Trial name
- NCT04011293
- Testing
- CNCT19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong University
Fungal Disease
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and…
- Trial name
- NCT07357038
- Testing
- Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematologic Malignancies
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy of TXA127 to reduce the incidence (Grade II-IV) of acute Graft-vs.-Host Disease (aGVHD) in adult subjects undergoing allogeneic peripheral blood stem cell transplantation…
- Trial name
- NCT01882387
- Testing
- TXA127
- Where
- 2 sites in United States
- Sponsor
- Tarix Pharmaceuticals
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
Cancer, Young Adult
Symptom Management for YA Cancer Survivors
Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as…
- Conditions
- Cancer, Young Adult, Pain, Psychological Distress
- Trial name
- NCT04035447
- Testing
- Behavioral Symptom Management for Young Adult Cancer Survivors
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Hematologic Malignancy, CAR-T Cell Therapy
CAR T-CELL Therapy Educational Video Trial
The purpose of this study is to test a new educational video to help patients and doctors talk about CAR-T cell therapy, a treatment being used in cancer. Educational video tool for patients receiving CAR-T cell therapy.
- Trial name
- NCT04280133
- Testing
- Educational Video Tool
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Stem Cell Transplant Complications
Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies
Patients affected by multiple myeloma undergone autologous stem cell transplantation (SCT) are enrolled at the moment of stem cell collection. They are randomized 1:1 in two groups at the moment of the graft.
- Trial name
- ZENITH (NCT03159845)
- Testing
- Zinc Sulfate Oral Product, Levofloxacin 500Mg Oral Tablet, Fluconazole 200mg tab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Graft Versus Host Disease
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor.
- Trial name
- NCT00720629
- Testing
- Visilizumab, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.